Faeth Therapeutics

Faeth Therapeutics (NASDAQ: FTH) is a clinical-stage oncology company pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Co-founded in 2019 by Anand Parikh and Oliver Maddocks, PhD, alongside world-leading cancer biologists including Dr. Lewis Cantley (discoverer of the PI3K pathway), Faeth was built on the core conviction that simultaneously suppressing multiple nodes of a biological pathway produces deeper, more durable tumor suppression than targeting a single node alone. The company's lead program, PIKTOR — a combination of serabelisib (PI3K-alpha inhibitor) and sapanisertib (mTORC1/2 inhibitor) — targets three PAM pathway nodes simultaneously. In February 2026, Faeth merged with Sensei Biotherapeutics in a transaction that included a concurrent $200 million private placement, with PIKTOR advancing as the combined publicly-traded company's lead clinical program.